Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS
Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS
复制标题
DOI：
10.1016/j.intimp.2020.106906
复制
发表时间：
2020-11-01
影响因子：
5.6
通讯作者：
Patel, Kavit
中科院分区：
文献类型：
--
作者：
Bodkhe, Shradha;Nikam, Mayuri;Patel, Kavit
磷酸二酯酶 4 抑制剂 (PDE4) 由于其广泛的抗炎作用而在气道炎症性疾病的治疗中引起了极大的兴趣。 Roflumilast 是一种选择性 PDE4 抑制剂，可抑制肺部和全身炎症并缓解气道疾病症状。哮喘和COPD是常见的慢性气道炎症性疾病，其病理生理学和临床表现尚不完全清楚。最近，出现了一种称为哮喘-慢性阻塞性肺病重叠（ACO）的病症，其具有两种疾病的重叠症状。新发现的PDE4抑制剂罗氟司特已展现出其治疗哮喘、慢性阻塞性肺病和ACOS的潜力。据说其在气道炎症性疾病中的作用机制是通过提高细胞内cAMP来发挥作用，并显示其抗炎作用。罗氟司特是一种很有前景的炎症性气道疾病治疗方法，具有许多显着的疗效。在本次综述中，我们提供了罗氟司特治疗慢性阻塞性肺病和哮喘的各种有前景的临床证据。然而，迄今为止还没有公开的临床证据证明罗氟司特在 ACOS 中的作用。尽管如此，ACOS的治疗机制仍可为临床应用提供参考。
Phosphodiesterase-4 inhibitors (PDE4) are of great interest for the treatment of airway inflammatory diseases due to its broad anti-inflammatory effects. Roflumilast is a selective PDE4 inhibitor that inhibits pulmonary and systemic inflammation and rallies symptoms in airway diseases. Asthma and COPD are common chronic airway inflammatory diseases having incompletely illustrious pathophysiology and clinical manifestations. Recently, the condition called Asthma- COPD Overlap (ACO) has been evolved having the overlapping symptoms of both diseases. The newly discovered PDE4 inhibitor, roflumilast has exposed its potential in the treatment of Asthma, COPD and ACOS. Its mechanism of action in airway inflammatory diseases are said to be exerts by elevating intracellular cAMP and shows its anti-inflammatory action. Roflumilast, a promising therapeutic approach in inflammatory airway diseases, has many significant outcomes. In this review, we have provided various promising clinical evidences of roflumilast in COPD and asthma. However, there is no published clinical evidence to date for the role of roflumilast in ACOS. Nevertheless, there are therapeutic mechanisms that provide a reference for clinical application for ACOS.